Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Search Science Hub
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
ERA 2024
Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial
ERA 2024
Get notified when materials for ERA 2024 and future congresses become available:
Slide decks
Posters
Videos ... and more.
Get notified when materials for ERA 2024 and future congresses become available:
Slide decks
Posters
Videos ... and more.
{{ error.$message }}
Success
We will notify you when new materials become available for ERA 2024 and future congresses.
We will keep you updated in your inbox:
Subscribe to receive updates on related congresses in the same disease area:
Almost Done